Keytruda sales, all indications, are 20B$ for the last 12 months.
Merck is already planning for the after-Keytruda (2028). They brought Keytruda into 400 clinical trials. So they would have the resources to bring PDT (and our best PDCs (TLD-1433, Rutherrin, other recent PDCs from Dr. McFarland on which TLT would still own rights)) to many more indications at the same time. They could invade all possible oncology indications like they did with Keytruda.
And if it's not Merck, it could be any other big pharma. JVs per indication or simply a buy out. so you can better assess the magnitude, if our results are extremely clear.
Si the clearer our Ph. 2 NMIBC data will be, the more negociation power we'll have. So let's hope for something crystal clear. Something like +10% above any competition for 450-days data on our first 25 patients, despite the first 12 underdosed, would be striking, especially if data on the 13 optimized patients is published. That would demonstrate how potent TLD-1433 can be! And this would act as an eye-opener to big pharmas. The gates would open and it would be to the best horse to win the prize.
It's all about market shares. It all comes down to market shares for big pharmas. One will move faster than the others.